Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
28 hedge funds and large institutions have $13.2M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
12% more funds holding
Funds holding: 25 → 28 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $13.3M → $13.2M (-$122K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$376K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$294K |
| 3 |
BlackRock
New York
|
+$89.5K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$87.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
-$295K |
| 2 |
JP Morgan Chase
New York
|
-$36.4K |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$21.2K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$10K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.87K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
26
Advisornet Financial
Minnetonka,
Minnesota
| $1K | – | – | – |
|
|
WAP
27
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| $1K | – | – | – |
|
28
Fidelity Investments
Boston,
Massachusetts
| $1K | +$1.09K | +75 | New |
|
|
29
Victory Capital Management
San Antonio,
Texas
| – | -$10K | -683 | Closed |
|
|
IA
30
IFP Advisors
Tampa,
Florida
| – | -$2K | -112 | Closed |
|
OPNT Hedge Fund Activity: Q4 2019 in Review
28 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q4 2019, worth a combined $13.2M — down 0.91% from $13.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new OPNT positions and 3 closed out — a net gain of 4 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $376K. The largest seller was Fondren Management, cutting an estimated $295K.
- 28 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q4 2019, up from 25 in Q3 2019.
- Funds reported $13.2M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q4 2019, down 0.91% quarter-over-quarter.
- 7 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of +4 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $376K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Fondren Management, an estimated $295K sold.
Based on aggregated 13F filings for Q4 2019.